This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.

Disclosed is a patch for alleviating cancerous pain. The patch is provided with a support layer and an adhesive layer laminated on the support layer. The adhesive layer contains an adhesive base and 150-225 mg of diclofenac sodium. One patch is used by being attached once per day.

Disclosed is a patch for alleviating cancerous pain. The patch is provided with a support layer and an adhesive layer laminated on the support layer. The adhesive layer contains an adhesive base and 150-225 mg of diclofenac sodium. One patch is used by being attached once per day.

In an embodiment, the present disclosure relates to a method to prevent or inhibit proliferation, growth and formation, or survival of protozoans, bacteria, or fungal cells. In some embodiments, the method includes administering a composition including a synthetic lysine analog, derivative, mimetic, or prodmg. In some embodiments, the synthetic lysine analog, derivative, mimetic, or prodmg interacts with the protozoans, bacteria, or fungal cells to prevent or inhibit proliferation, growth and formation, or survival of the protozoans, bacteria, or fungal cells. In an additional embodiment, the present disclosure relates to a composition to prevent or inhibit proliferation, growth and formation, or survival of protozoans, bacteria, or fungal cells. In some embodiments, the composition includes a synthetic lysine analog, derivative, mimetic, or prodrug.

In an embodiment, the present disclosure relates to a method to prevent or inhibit proliferation, growth and formation, or survival of protozoans, bacteria, or fungal cells. In some embodiments, the method includes administering a composition including a synthetic lysine analog, derivative, mimetic, or prodmg. In some embodiments, the synthetic lysine analog, derivative, mimetic, or prodmg interacts with the protozoans, bacteria, or fungal cells to prevent or inhibit proliferation, growth and formation, or survival of the protozoans, bacteria, or fungal cells. In an additional embodiment, the present disclosure relates to a composition to prevent or inhibit proliferation, growth and formation, or survival of protozoans, bacteria, or fungal cells. In some embodiments, the composition includes a synthetic lysine analog, derivative, mimetic, or prodrug.

A surgical device includes a substrate and a first coating that covers at least a portion of the substrate. The first coating includes a first polymer. The first coating having antibiotics dispersed in the first polymer such that the first polymer releases the antibiotics as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second polymer. The second polymer includes an alginate. The second coating has a hemostatic agent dispersed in the second polymer such that the second polymer releases the hemostatic agent as the second polymer degrades. The hemostatic agent is selected from epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose. In some embodiments, systems and methods are disclosed.

A surgical device includes a substrate and a first coating that covers at least a portion of the substrate. The first coating includes a first polymer. The first coating having antibiotics dispersed in the first polymer such that the first polymer releases the antibiotics as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second polymer. The second polymer includes an alginate. The second coating has a hemostatic agent dispersed in the second polymer such that the second polymer releases the hemostatic agent as the second polymer degrades. The hemostatic agent is selected from epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose. In some embodiments, systems and methods are disclosed.

The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula: ##STR00001##

The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula: ##STR00001##

Provided herein are compositions and methods for treating succinic semialdehyde dehydrogenase deficiency (SSADHD). Compositions may include a gene encoding a functional succinic semialdehyde dehydrogenase (SSADH) enzyme, such as ALDH5A1, operably linked to a targeting vector. The functional SSADII enzyme is envisioned to lower the levels of circulating gamma-hydroxybutyric acid (GHB) and γ-aminobutyric acid (GABA). In some embodiments, combination therapies are envisioned, comprising administering to the subject therapeutically effective amounts of a combination of a composition comprising a gene encoding a functional SSADII enzyme operably linked to a targeting vector; one or more mTOR inhibitors; and a GABA-T inhibitor. Suitable mTOR inhibitors include rapamycin, while suitable GABA-T inhibitors include vigabatrin.